IBO

Impact BioMedical Inc.

Impact BioMedical Inc. (IBO) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Momentum (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C-
Factor Score 1.9 / 5.0
Growth
C
Factor Score 2.5 / 5.0
Profitability
C+
Factor Score 2.6 / 5.0
Momentum
D+
Factor Score 1.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.4
EV / EBITDA -9.6
Rev Growth YoY 16.7%
Gross Margin 0.0%
Price Return 3M -22.8%
Price Return 12M -39.3%
Catalyst Signal 0.00
Market Cap $37.2M
TTM Revenue $38.0K
Price / Sales 977.7
ROE 71.2%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C- (1.9) C (2.5) C+ (2.6) D+ (1.7) C+ (2.6) C (2.3)
2026-11-05 C- (1.9) F (0.5) C- (1.9) D+ (1.7) C+ (2.7) D+ (1.7)
2026-10-29 C- (1.9) F (0.5) C- (1.9) D+ (1.8) C+ (2.7) D+ (1.8)
2026-10-22 C- (1.9) F (0.5) C- (1.9) C- (2.0) C+ (2.6) D+ (1.8)
2026-10-15 C- (1.9) F (0.5) C- (1.9) D+ (1.7) C+ (2.6) D+ (1.7)
Page 1 of 3